Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common altitude sickness drug help heart failure patients shed excess fluid?

NCT ID NCT07737964

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This phase 3 trial investigates whether adding acetazolamide—a drug often used for altitude sickness—to standard diuretics can improve fluid removal in people with heart failure who experience sudden fluid buildup. Participants take the medication for up to five days while being monitored remotely via a connected scale. The study aims to see if more patients lose over 2 kilograms of fluid weight compared to those receiving only standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acetazolamide added to standard loop diuretics (furosemide)
What this could lead to
If it works, this could offer a better way to relieve fluid buildup in heart failure patients without needing hospitalization.
What could go wrong
This is an early-phase trial with 366 participants; acetazolamide may not improve outcomes and could cause side effects like electrolyte imbalances or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 366 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Known HF with impaired, midly-reduced or preserved LVEF * Under guideline directed medical therapy for HF according to ESC Heart Failure Guidelines applicable at inclusion * Previously followed (or included at hospital discharge) by remote monitoring allowing daily weight by connected scale (i.e. Careline®, Optified-self®, NewCard®, Implicity®) * Under furosemide diuretic treatment ≥ 20mg/day for at least 30 days prior to inclusion * Current unplanned hospitalization or unplanned/emergent consultation for acute/decompensation HF Exclusion Criteria: * Subject unable to express their consent and sign informed consent form * Subject not covered by public health insurance * Refusal to participate (absence of informed consent). * Subject under guardianship, legal protection, or deprived of liberty. * Pregnant or breastfeeding women. * Subject under law protection and prisoners * Women of child bearing potential, unless they are using an effective method of birth control (i.e. oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner) * Subject unable to comprehend or adhere to the protocol and follow-up * Concurrent participation in another interventional study. * Chronic ventricular assist device or heart transplant patients. * Acute heart failure from recent acute coronary syndrome (\< 1 month). * Severe chronic renal failure or dialysis (GFR \< 20 ml/min). * History of renal colic, hyperchloremic acidosis and wheat allergy (other than coeliac disease) * Known severe hepatic insufficiency defined by a PTT \< 50% or a Child-Pugh score C and/or a known (clinial or biological) supplemented adrenal insufficiency * Intolerance to sulphonamides * Hypersensitivity to the active substance (Acetazolamide) or to any of the excipients (Calcium carbonate, wheat starch, gelatine, magnesium stearate) * Concomitant use of carbamazepine or quinidinics (hydroquinidine, quinidine) * Low cardiac output syndrome/cardiogenic shock. * Current use of acetazolamide or any other carbonic anhydrase inhibitor, including but not limited to topical ophthalmic formulations (e.g., brinzolamide, dorzolamide, methazolamide) * Concomitant use of lithium, valproic acid and valpromide * Current use of high-dose aspirin (\>300 mg/day). Non-randomization criteria (Criteria should be controlled before patients' randomization) : * False alarm * Time between alarm and randomization \> 48h * Subject who declines his participation * Loss of study treatments or unable to take it at D0 * Hemodynamic instability justifying an urgent hospitalization * If applicable, positive urine pregnancy test

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Avignon Hospital

    Avignon, France

  • Bicêtre Hospital

    Le Kremlin-Bicêtre, France

  • Cardiovascular Institute - Grenoble Mutualist Hospital Group

    Grenoble, France

  • Chartres Hospital

    Chartres, France

  • Cholet Hospital

    Cholet, France

  • Dreux Hospital

    Dreux, France

  • Ellipse Center Strasbourg

    Strasbourg, France

  • Hospital Beziers

    Béziers, France

  • Louis Pradel Hospital

    Lyon, France

  • Pôle Santé Sud - Le Mans

    Le Mans, France

  • Regional University Hospital Nancy

    Nancy, France

  • Sainte Musse Hospital Toulon

    Toulon, France

  • Sud Francilien Hospital

    Corbeil-Essonnes, France

  • The Confluent Private Hospital

    Nantes, France

  • University Hospital Amiens-Picardie

    Amiens, France

  • University Hospital Angers

    Angers, France

  • University Hospital Besançon

    Besançon, France

  • University Hospital Bordeaux

    Bordeaux, France

  • University Hospital Brest

    Brest, France

  • University Hospital Caen

    Caen, France

  • University Hospital Grenoble Alpes

    Grenoble, France

  • University Hospital Nîmes

    Nîmes, France

  • University Hospital Toulouse

    Toulouse, France

  • University hospital Montpellier

    Montpellier, France

  • Valenciennes Hospital

    Valenciennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.